Slide 1: Making life easier
Conference call presentation 9M 2023/24 Making life easier Strive25: Sustainable Growth Leadership Theresa Continence Care user Ostomy Care | Continence Care | Advanced Wound Care | Interventional Urology | Voice and Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q3 2023/24 financial result in line with guidance
NEW IMAGE Q3 2023/24 financial result Otto: add picture in line with guidance with Peristeen Light Update picture Organic Reported ROIC growth EBIT margin 8% 27% * * 15% ** Update picture *before special items **after tax and before special items 3 Thomas | Continence Care user
Slide 4: 9M 2023/24 organic growth of 8%, driven by Chronic Care and double-digit growth
9M 2023/24 organic growth of 8%, driven by Chronic Care and double- digit growth in Voice & Respiratory Care and Advanced Wound Care 9M 2023/24 revenue by business area 9M 2023/24 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growt
Slide 5: 9M reported revenue grew 10% with Kerecis contribution and currency impact
9M reported revenue grew 10% with ~4%-points contribution from the Kerecis acquisition and ~2%-points negative impact from currencies 9M 2023/24 Revenue development (mDKK) 9M 2023/24 highlights • Reported revenue increased by DKK 1,803 million or 10% vs. last year. +1,803 • Organic growth was 8% or
Slide 6: Reported EBIT margin of 27% in 9M, impacted by currency headwind and Kerecis
Reported EBIT margin of 27%1 in 9M, impacted by currency headwind and ~100 basis points dilution from Kerecis, as expected 9M 2023/24 EBIT margin development before special items (%) 9M 2023/24 highlights • Gross margin was 68%, compared to 67% last year 1.1 -1.8 • Positive impact from: decrease in
Slide 7: Adj. FCF of DKK 2,314 million in 9M
Adj. FCF of DKK 2,314 million in 9M. Operating cash flow impacted by the extraordinary tax payment related to the Atos Medical IP transfer FCF development1 9M 2023/24 highlights • Free cash flow for 9M 2023/24 was an outflow of DKK 186 million vs an 98 inflow of DKK 1,690 million last year, impacted
Slide 8: Unchanged FY 2023/24 financial guidance
Unchanged FY 2023/24 financial guidance with organic growth expected around 8% and EBIT margin* of 27-28% Organic revenue growth Around 8% Reported revenue growth in DKK 10-11% Reported EBIT margin* 27-28% Effective tax rate Around 22% Capital expenditures Around 1.3 bn DKK *before special items 8
Slide 9: Making life easier for people with intimate healthcare needs
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding